Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Coverage · News & Announcements · Infectious Disease, Pediatrics, Internal Medicine +1 moreMedium impact

Coverage of Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) for Measles Post-Exposure Prophylaxis in Medicare Advantage Members

Act
by Jan 16, 2026
Effective date
Jan 16, 2026
Identified
Jun 19, 2026

Summary

This recent policy (effective 01/16/2026) establishes Medicare Advantage coverage for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) when used for measles post-exposure prophylaxis. Billing teams must recognize this as a covered service for eligible MA members and ensure proper coding and documentation to support claims.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Jan 16, 2026 · 6 steps
01Billing team must update billing system configuration to recognize IVIG and SCIG as covered services for measles post-exposure prophylaxis under Medicare Advantage plans.
02Ensure claims are submitted with appropriate diagnosis code Z20.8 (exposure to communicable disease—measles) or related measles exposure codes.
03Verify that prior authorization requirements (if any) are documented in the MA plan rules and implement into workflow.
04Update claim templates and provider education materials to reflect this coverage.
05Verify that claims for IVIG/SCIG with measles post-exposure indication are processed without automatic denial.
06Confirm with the MA plan whether prior authorization is required before administration.

Codes mentioned

J1561J1566J1575J2788Q4325

Original notice

Coverage of Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) for Measles Post-Exposure Prophylaxis in Medicare Advantage Members
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.009z, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)LowEffective Jul 1, 2026 · Medical Policy08.00.13ao, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)LowEffective Jul 1, 2026 · Medical PolicyMA08.009w, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)MediumEffective Jan 1, 2025 · Medical PolicyMA08.009y, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)MediumEffective Apr 1, 2026 · Medical PolicyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesInfectious DiseasePediatricsInternal MedicineAllergy & ImmunologyCode J1561Code J1566Code J1575Code J2788Code Q4325

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account